Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

1.

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM.

J Clin Oncol. 2006 Jul 1;24(19):3089-94.

PMID:
16809734
[PubMed - indexed for MEDLINE]
Free Article
2.

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW.

Cancer. 2009 Aug 15;115(16):3670-9. doi: 10.1002/cncr.24429.

PMID:
19536890
[PubMed - indexed for MEDLINE]
Free Article
3.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
[PubMed - indexed for MEDLINE]
4.

Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.

Patel PH, Kockler DR.

Ann Pharmacother. 2008 Jan;42(1):91-8. Epub 2007 Dec 19. Review.

PMID:
18094343
[PubMed - indexed for MEDLINE]
5.

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.

Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29.

PMID:
19042080
[PubMed - indexed for MEDLINE]
6.

Sipuleucel-T (APC8015) for prostate cancer.

So-Rosillo R, Small EJ.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1163-7. Review.

PMID:
17020451
[PubMed - indexed for MEDLINE]
7.

Sipuleucel-T: in metastatic castration-resistant prostate cancer.

Plosker GL.

Drugs. 2011 Jan 1;71(1):101-8. doi: 10.2165/11206840-000000000-00000. Review.

PMID:
21175243
[PubMed - indexed for MEDLINE]
8.

Advances in prostate cancer immunotherapies.

Basler M, Groettrup M.

Drugs Aging. 2007;24(3):197-221. Review.

PMID:
17362049
[PubMed - indexed for MEDLINE]
9.

Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.

Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer PF, Jones LA, Xu Y, Kylstra JW, Frohlich MW.

Clin Cancer Res. 2011 Jul 1;17(13):4558-67. doi: 10.1158/1078-0432.CCR-10-3223. Epub 2011 May 10.

PMID:
21558406
[PubMed - indexed for MEDLINE]
Free Article
10.

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

Di Lorenzo G, Ferro M, Buonerba C.

BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16. Review.

PMID:
22177289
[PubMed - indexed for MEDLINE]
11.

Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis.

Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, Reis RB.

Int Braz J Urol. 2012 Nov-Dec;38(6):717-27. Review.

PMID:
23302410
[PubMed - indexed for MEDLINE]
Free Article
12.

Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.

Buonerba C, Ferro M, Di Lorenzo G.

Expert Rev Anticancer Ther. 2011 Jan;11(1):25-8. doi: 10.1586/era.10.180. Review.

PMID:
21166508
[PubMed - indexed for MEDLINE]
13.

Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.

McKarney I.

Issues Emerg Health Technol. 2007 Sep;(101):1-4.

PMID:
17763575
[PubMed - indexed for MEDLINE]
14.

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlović S.

Prostate. 2004 Aug 1;60(3):197-204.

PMID:
15176049
[PubMed - indexed for MEDLINE]
15.

Prostate cancer vaccines: current status and future potential.

Doehn C, Böhmer T, Kausch I, Sommerauer M, Jocham D.

BioDrugs. 2008;22(2):71-84. Review.

PMID:
18345705
[PubMed - indexed for MEDLINE]
16.

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW.

Urology. 2013 Jun;81(6):1297-302. doi: 10.1016/j.urology.2013.01.061. Epub 2013 Apr 9.

PMID:
23582482
[PubMed - indexed for MEDLINE]
17.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

PMID:
17999840
[PubMed - indexed for MEDLINE]
Free Article
18.

Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.

Beinart G, Rini BI, Weinberg V, Small EJ.

Clin Prostate Cancer. 2005 Jun;4(1):55-60.

PMID:
15992463
[PubMed - indexed for MEDLINE]
19.

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.

Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN.

Cancer Control. 2013 Jan;20(1):7-16. Review.

PMID:
23302902
[PubMed - indexed for MEDLINE]
Free Article
20.

Current vaccination strategies for prostate cancer.

Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S.

Eur Urol. 2012 Feb;61(2):290-306. doi: 10.1016/j.eururo.2011.09.020. Epub 2011 Oct 3. Review.

PMID:
22001436
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk